Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
12. März 2020 09:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform...
Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
03. März 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Therapeutics CEO Issues Shareholder Update
10. Februar 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products,...
In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.
03. Februar 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study
17. Dezember 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment
03. Dezember 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Therapeutics CEO Issues Shareholder Update
12. November 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
04. November 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. ...
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs
16. September 2019 12:20 ET
|
Pluristem Therapeutics, Inc.
PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd...
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
09. September 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced...